New findings from the RESPONSE trial confirm Novartis‘s ruxolitinib provides comprehensive benefits for polycythemia vera (PV) patients who don’t adequately respond to hydroxyurea. The oral JAK1/2 inhibitor not only maintains target hematocrit levels but also delivers rapid, clinically meaningful relief from debilitating symptoms – particularly severe aquagenic pruritus (itching), often within just 48 hours of treatment. Key advantages of ruxolitinib include a superior control of blood counts (hematocrit, WBC, platelets), dramatic improvement in quality-of-life symptoms like itching and fatigue, and effective reduction of spleen enlargement. Also, ruxolitinib is better tolerated than interferon in many patients. These findings reinforce its role as a second-line standard for PV patients failing hydroxyurea, with real-world evidence showing sustained efficacy beyond clinical trial settings.

OxyDial recognizes ruxolitinib’s dual impact on both disease progression and symptom burden. As PV treatment evolves, ensuring global access to these advanced therapies remains critical for improving outcomes in this chronic blood disorder.

Read more: https://lnkd.in/ePAYTn-r

#PolycythemiaVera #MPN #Ruxolitinib #JAKinhibitor #Hematology #BloodCancer #PatientCare #Novartis